ProCertus BioPharm, Inc. is an oncology-based pharmaceutical company established in 1997 with administrative and research facilities located in Madison, Wisconsin. The ProCertus mission is: To discover and develop innovative pharmaceutical products that protect cancer patients against the side effects of their therapy. The Company holds exclusive world-wide license to a breakthrough technology platform based upon the research and development activities of Dr. William E. Fahl, a world-recognized expert in cancer research with the McArdle Laboratory for Cancer Research at the University of Wisconsin-Madison. Based on a common technology platform, the Company has developed DermX, ProDermaCelÔ and OralX in parallel through animal proof of concept, and will advance all three product candidates to safety and efficacy studies in normal human subjects and cancer patients. ProCertus management believes that ProDermaCelÔ, DermX, and OralX will fundamentally change the quality of life for cancer patients.
Polydex Pharmaceuticals Limited is engaged in the research, development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market, and also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. The Company conducts its business operations through its subsidiaries Dextran Products and Chemdex. Polydex Pharmaceuticals focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. The Company is a party to a Research Agreement with the University of British Columbia, and a number of Canadian hospitals to develop Low Molecular Weight Dextran. It is also developing Cellulose Sulphate (Ushercell), a high molecular weight Cellulose Sulfate envisioned for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases. (Source: 10-K)
Thallion Pharmaceuticals Inc., formerly known as Ecopia BioSciences Inc., is a biotechnology company focused on developing pharmaceutical products in the areas of oncology and infectious diseases. The Company’s products include Shigamabs, which is a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections, ECO-4601, a molecule with the potential to treat multiple solid tumors, and CAP-232, a peptide with potential efficacy in multiple oncology indications. Thallion Pharmaceuticals Inc. was formed by the amalgamation of Ecopia BioSciences Inc. and Caprion Pharmaceuticals Inc. on March 14, 2007. On July 10, 2007, the Company sold its 80% interest in its wholly owned proteomics business, Caprion Proteomics General Partenership, to Caprion Proteomics Inc., a company formed by Great Point Partners, LLC of Greenwich, Connecticut. (Source: ARS)
BioDiem Ltd. operates in the biopharmaceutical industry developing and commercializing biomedical research. The Company has acquired a license to commercialize influenza vaccine technologies from the Institute of Experimental Medicine. The Company’s live attenuated influenza vaccine (LAIV) was licensed in Noblin International. BioDiem, through its collaboration with the IEM continues to complete research characterizing the benefits of LAIV for the treatment of influenza. The Company has obtained the rights through an option to take a license to a synthetic peptide BDM-E, for the treatment of retinal eye diseases. (Source: ARS)
Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company's products are based on the EVadeÔ Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases. The EVadeÔ Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin. The Company is in the late pre-clinical stages of development of QBI-139 and is expecting to file an Investigational New Drug Application in the first half of 2008. Phase I human clinical trials are expected to begin soon after filing the IND. Second generation products are under development and pre-clinical work is ongoing.
Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout our long history, we have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. We are committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses. We have a long standing tradition of building relationships, based on the highest standards, with patients, physicians, employees, partners and other key stakeholders. In the last ten years, we have focused on expanding our pan-European infrastructure, and have moved to strengthen the Research & Development base of the company. As a result, we are now positioned with: a strong portfolio of internal development projects, principally in the areas of gastroenterology, hepatology, incontinence and pain management an extensive sales and marketing organisation an established manufacturing base In addition to developing, manufacturing and marketing its own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and launch of innovative pharmaceutical products across Europe. We value our development partnerships as, together with our own in-house product development, they support our growth ambitions and will help to facilitate our continued business expansion. We have the resources to bring products to market on a pan-European or single country basis, combining sales and marketing expertise together with all development, clinical research, product registration or manufacturing resources which our partners require. We brought our lead product, Movicol®, to market from inception within three years, demonstrating the clear benefits which our focused product development strategies can deliver. In the years ahead Norgine will continue to implement this successful strategy, building on our established infrastructure, strengthening our pan-European presence and collaborating with like-minded companies and organisations. By consolidating our successes, we can ensure we meet the challenges of an exciting future.
http://www.alteatherapeutics.com
Altea Therapeutics is an emerging specialty pharmaceutical company developing and commercializing products based on a new transdermal patch technology that can deliver therapeutic levels of water-soluble small drugs, therapeutic proteins, carbohydrates, and vaccines through the skin in a convenient, painless and cost-effective manner. Altea Therapeutics has demonstrated in several clinical studies that its patented PassPort Transdermal System achieves what existing transdermal patches are unable to do, namely the delivery through the skin of compounds that are typically administered by needle injections. The company is currently conducting clinical trials in the United States for its products, which include a Transdermal Basal Insulin Patch designed to provide continuous delivery of insulin for people with Type 1 and Type 2 diabetes and a Transdermal Fentanyl Citrate Patch that enables rapid and safe management of moderate to severe pain. Furthermore, the company is in clinical and pre-clinical development with a number of product candidates, including an undisclosed transdermal protein patch, a parathyroid hormone analog transdermal patch for osteoporosis, and an atypical antipsychotic transdermal patch for the management of psychosis. Altea Therapeutics is the recipient of the Frost & Sullivan 2007 Technology Innovation Award for its development of the PassPort System.
LEO Pharma is among the world's leading companies in topical dermatology and parenteral treatment of thromboembolic disorders. We pride ourselves on the results that the dedicated and motivated people at LEO achieve. The creativity, knowledge and experience accumulated in our organisation together with our financial independence are pivotal to our aim of getting safe and efficacious drugs on the market.
Rosemont Pharmaceuticals Ltd. is a leading developer, manufacturer and supplier of high quality oral liquid medicines which are used by patients who are unable or unwilling to swallow solid medications. We are based in Leeds, West Yorkshire in the UK, and employ approximately 170 people. Through our significant R&D expertise, we have developed over 90 oral liquid medicines, and our customers see us as 'The Source of Liquid Solutions'.
Sosei Group Corporation is a Japan-based biopharmaceutical company. Its pharmaceutical business include the research, development and sale of pharmaceutical drugs. The Company's product line includes the NVA237, QVA149, AD 923, SOU-003, AD 337 and SOH-075 series. The products are used for chronic obstructive pulmonary disease, cancer breakthrough pain, nocturia and noctural enuresis, fibromyalgia syndrome, as well as emergency contraception. The Company has six consolidated subsidiaries. (Source: ARS)
Photocure ASA is a Norway-based pharmaceutical company that develops and sells pharmaceuticals and medical devices based on its photodynamic technology, which is used to detect and cure diseases. The Company targets the dermatology and oncology markets. Its main products comprise: Metvix, which is used for the treatment of skin cancer and pre-cancerous skin lesions; Aktilite CL 16 and CL 128, which are lamps used in photodynamic therapy (PDT) in combination with Metvix, and Hexvix, which is utilized for the detection of bladder cancer. The Company also develops photochemical internalization (PCI), a technology for light-directed drug delivery specifically into diseased cells. Photocure ASA operates through two subsidiaries PCI Biotech Holding ASA and PCI Biotech AS, and is active in Norway, Sweden, Denmark and Finland. The Company is headquartered in Oslo, Norway.
Caprion offers its employees a dynamic and stimulating work environment, encouraging continuous innovation and the sharing of knowledge and ideas. We offer a comprehensive compensation package, including a competitive salary, participation in an employee stock option plan, a group insurance plan and relocation assistance. Our 54,000 square foot world-class proteomics facility is situated in the Technoparc of St-Laurent, Quebec and includes a fitness center, coffee bar, employee lounge and other exciting amenities. We are in close proximity to Pierre-Elliot Trudeau International Airport, and downtown Montreal. Montreal is a unique urban environment, culturally rich, ethnically diverse and economically modern and dynamic.
Nexmed, Inc. is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and patented topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin’s natural barrier properties and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity. (Source: 10-K)
Schwarz Pharma Ltd is the UK affiliate of Schwarz Pharma AG. Since the present company was founded in 1946, Schwarz Pharma has grown from a small family business in Germany into one of the most influential pharmaceutical companies in Europe. In recent years a major contribution to this success has been provided by the International Division, which comprises affiliate companies located in the UK, Italy, USA, China, France, Ireland and Poland. Schwarz Pharma Limited was established in 1979 with headquarters in Buckinghamshire. Expansion has been continuous, derived from a growing range of products for the GP and hospital markets. The company's products appear in the top ranks of the UK performance listings and Schwarz Pharma is one of Europe's top 50 leading pharmaceutical companies.
Insmed Incorporated (Insmed) is a development stage biopharmaceutical company specializing in recombinant protein drug development. The Company is developing a pipeline of products targeted at the therapeutic areas of autoimmune, neutropenia and anemia. On the protein front, Insmed’s product IPLEX is being developed in various stages as a treatment for several medical conditions, with an initial focus on Myotonic Muscular Dystrophy (MMD) and Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease) in Italy. Other areas where IPLEX has also shown potential include HIV-associated Adipose Redistribution Syndrome (HARS) and Retinopathy of Prematurity (ROP). IPLEX has United States Food and Drug Administration (FDA) approval. The Company operates an FDA-approved commercial biologics manufacturing facility in Boulder, Colorado. (Source: 10-K)
Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a global pharmaceutical company with proven research capabilities. The Company produces active pharmaceutical ingredients (APIs) and intermediates, and finished dosage forms and biologics products, and markets them globally, with a focus on India, the United States, Europe and Russia. The Company is vertically integrated and uses its active pharmaceutical ingredients and intermediates in its own finished dosage products. Dr. Reddy’s Laboratories Limited conducts basic research in the areas of cancer, diabetes, metabolic disorders, cardiovascular disease, inflammation and bacterial infection. The Company operates through five segments: formulations, active pharmaceutical ingredients and intermediates, generics, custom pharmaceutical services (CPS) and drug discovery. In September 2008, the Company announced the launch of Promius Pharma, its wholly owned subsidiary.
Eurand N.V. is a specialty pharmaceutical company that develops, manufactures and commercializes pharmaceutical and biopharmaceutical products based on its drug formulation technologies. The Company has applied its technologies to drug products in a range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition and respiratory. In December 2007, it completed the rolling submission of a new drug application (NDA) for its lead product candidate, Zentase (formerly known as EUR-1008), which is being evaluated for the treatment of exocrine pancreatic insufficiency (EPI). The NDA was accepted for filing and granted priority review in February 2008. In addition to Zentase the Company is also developing a number of other products both for its collaboration partners and its portfolio. As of December 2007, the most advanced of its pipeline products include two co-development products and one product candidate. (Source: 20-F)
QLT Inc. is a global biopharmaceutical company with two commercial products, Visudyne and Eligard, which were derived from its two technology platforms, photodynamic therapy and Atrigel. The Company's research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. Since its acquisition of ForSight Newco II, Inc. (QLT Plug Delivery, Inc.) on October 18, 2007, the Company is also developing an ocular punctal plug drug delivery system. QLT's first commercial product was in the field of photodynamic therapy (PDT), which uses photosensitizers (light activated drugs) in the treatment of disease. The Company's commercial product, Visudyne, utilizes photodynamic therapy (PDT) to treat the eye disease known as wet age related macular degeneration (AMD). In October 2007, QLT Inc. completed the acquisition of ForSight Newco II, Inc.
Biovail Corporation (Biovail) is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company is engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products. Its main therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease. The primary markets for its products are the United States and Canada. Biovail has a portfolio of drug-delivery technologies includes controlled release, enhanced absorption, rapid absorption, taste masking, and oral disintegration technologies, among others. In September 2008, Biovail acquired Prestwick Pharmaceuticals, Inc., a company that holds the Canadian and United States rights to Xenazine (tetrabenazine tablets).
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory